177 related articles for article (PubMed ID: 35625893)
1. Combination of Elacridar with Imatinib Modulates Resistance Associated with Drug Efflux Transporters in Chronic Myeloid Leukemia.
Alves R; Gonçalves AC; Jorge J; Almeida AM; Sarmento-Ribeiro AB
Biomedicines; 2022 May; 10(5):. PubMed ID: 35625893
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in combination with Imatinib overcomes resistance in Chronic myeloid leukaemia.
Alves R; Gonçalves AC; Jorge J; Alves J; Alves da Silva A; Freitas-Tavares P; Nascimento Costa JM; Almeida AM; Sarmento-Ribeiro AB
Med Oncol; 2019 Feb; 36(3):30. PubMed ID: 30796703
[TBL] [Abstract][Full Text] [Related]
3. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
4. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
5. Distinct interaction of nilotinib and imatinib with P-Glycoprotein in intracellular accumulation and cytotoxicity in CML Cell Line K562 cells.
Yamakawa Y; Hamada A; Uchida T; Sato D; Yuki M; Hayashi M; Kawaguchi T; Saito H
Biol Pharm Bull; 2014; 37(8):1330-5. PubMed ID: 25087954
[TBL] [Abstract][Full Text] [Related]
6. TCF7 knockdown inhibits the imatinib resistance of chronic myeloid leukemia K562/G01 cells by neutralizing the Wnt/β‑catenin/TCF7/ABC transporter signaling axis.
Zhang H; Wang Y; Yang H; Huang Z; Wang X; Feng W
Oncol Rep; 2021 Feb; 45(2):557-568. PubMed ID: 33416164
[TBL] [Abstract][Full Text] [Related]
7. Silencing of suppressor of cytokine signaling-3 due to methylation results in phosphorylation of STAT3 in imatinib resistant BCR-ABL positive chronic myeloid leukemia cells.
Al-Jamal HA; Jusoh SA; Yong AC; Asan JM; Hassan R; Johan MF
Asian Pac J Cancer Prev; 2014; 15(11):4555-61. PubMed ID: 24969884
[TBL] [Abstract][Full Text] [Related]
8. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
[TBL] [Abstract][Full Text] [Related]
9. Tyrosine kinase inhibitor resistance in chronic myeloid leukemia cell lines: investigating resistance pathways.
Tang C; Schafranek L; Watkins DB; Parker WT; Moore S; Prime JA; White DL; Hughes TP
Leuk Lymphoma; 2011 Nov; 52(11):2139-47. PubMed ID: 21718141
[TBL] [Abstract][Full Text] [Related]
10. The role of long noncoding RNA HOTAIR in the acquired multidrug resistance to imatinib in chronic myeloid leukemia cells.
Wang H; Li Q; Tang S; Li M; Feng A; Qin L; Liu Z; Wang X
Hematology; 2017 May; 22(4):208-216. PubMed ID: 27875938
[TBL] [Abstract][Full Text] [Related]
11. Constitutive overexpression of P-glycoprotein, rather than breast cancer resistance protein or organic cation transporter 1, contributes to acquisition of imatinib-resistance in K562 cells.
Hirayama C; Watanabe H; Nakashima R; Nanbu T; Hamada A; Kuniyasu A; Nakayama H; Kawaguchi T; Saito H
Pharm Res; 2008 Apr; 25(4):827-35. PubMed ID: 17934801
[TBL] [Abstract][Full Text] [Related]
12. Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation.
Baran Y; Bielawski J; Gunduz U; Ogretmen B
J Cancer Res Clin Oncol; 2011 Oct; 137(10):1535-44. PubMed ID: 21833718
[TBL] [Abstract][Full Text] [Related]
13. Novel pharmacological approach for the prevention of multidrug resistance (MDR) in a human leukemia cell line.
Gupta SK; Singh P; Chhabra R; Verma M
Leuk Res; 2021 Oct; 109():106641. PubMed ID: 34144313
[TBL] [Abstract][Full Text] [Related]
14. The BCRP inhibitor febuxostat enhances the effect of nilotinib by regulation of intracellular concentration.
Ito F; Miura M; Fujioka Y; Abumiya M; Kobayashi T; Takahashi S; Yoshioka T; Kameoka Y; Takahashi N
Int J Hematol; 2021 Jan; 113(1):100-105. PubMed ID: 33025461
[TBL] [Abstract][Full Text] [Related]
15. [Effect of cryptotanshinone on imatinib sensitivity and P-glycoprotein expression of chronic myeloid leukemia cells].
Ge YQ; Cheng RB; Yang B; Huang Z; Chen Z
Zhongguo Zhong Yao Za Zhi; 2015 Jun; 40(12):2389-95. PubMed ID: 26591531
[TBL] [Abstract][Full Text] [Related]
16. Contribution of BCR-ABL-independent activation of ERK1/2 to acquired imatinib resistance in K562 chronic myeloid leukemia cells.
Nambu T; Araki N; Nakagawa A; Kuniyasu A; Kawaguchi T; Hamada A; Saito H
Cancer Sci; 2010 Jan; 101(1):137-42. PubMed ID: 19843070
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of Smad4 expression confers chemoresistance against imatinib mesylate to chronic myeloid leukemia K562 cells.
Zhang J; Zhang M; Liang Y; Liu M; Huang Z
Hematology; 2022 Dec; 27(1):43-52. PubMed ID: 34957936
[No Abstract] [Full Text] [Related]
18. Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells.
Peng XX; Tiwari AK; Wu HC; Chen ZS
Chin J Cancer; 2012 Feb; 31(2):110-8. PubMed ID: 22098951
[TBL] [Abstract][Full Text] [Related]
19. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
20. Use of deferasirox, an iron chelator, to overcome imatinib resistance of chronic myeloid leukemia cells.
Kim DS; Na YJ; Kang MH; Yoon SY; Choi CW
Korean J Intern Med; 2016 Mar; 31(2):357-66. PubMed ID: 26874514
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
